Lupin Counts On Generic Spiriva Launch In Q4 To Turn US Tide
Cuts Manufacturing Workforce
Even as it prepares for competition from an authorized generic, Lupin expects a launch of its generic to Boehringer’s blockbuster Spiriva in the fourth quarter of FY23. It hopes the launch will help its position in the US, where it has exited low margin products amid heightened competition, leading in turn to manufacturing job losses in India
You may also be interested in...
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
Looking to provide evidence of its extended measures to improve quality, compliance and oversight, Lupin has received positive news from the FDA for its US-based manufacturing facility in Somerset, New Jersey.